Wegovy Tracker - log injections, weight, and side effects
Wegovy is a once-weekly injection of semaglutide. This page explains how to track a Wegovy treatment with Dosley and links every medical fact to the FDA-approved label.
Wegovy is the brand name for semaglutide approved for chronic weight management in adults and certain adolescents who meet the indication criteria, used alongside a reduced-calorie diet and increased physical activity. Because each treatment plan looks slightly different - different starting amounts, ramp schedules, and side-effect timelines - keeping a personal log helps you and your prescriber see how things are going. Dosley is a private tracker for your injections, weight changes, and side-effect notes. It is not a medical device and does not give medical advice. The information below summarises the publicly available FDA-approved label so the page sits next to your tracker rather than inside it. If anything here differs from what your clinician has told you, follow your clinician.
At a glance
- Active ingredient
- Semaglutide 1
- Drug class
- GLP-1 receptor agonist 1
- Manufacturer
- Novo Nordisk 2
- FDA approval
- June 2021 (NDA 215256) 3
- Indication
- Chronic weight management in adults and certain adolescents who meet the BMI criteria, alongside diet and increased physical activity 1
- Schedule
- Once weekly, subcutaneous injection 1
- Starting dose
- 0.25 mg once weekly 1
- Maximum adult dose
- 2.4 mg once weekly 1
- Missed-dose window
- Take if more than 2 days remain before the next scheduled day; otherwise skip 1
- Storage
- Refrigerated at 2–8°C until first use; in-use room-temperature limits given on the label and patient leaflet 1
Important safety information
In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Wegovy is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2. 1
Contraindications
Common side effects
Discuss benefits and risks with your healthcare provider before starting or continuing this medication.
Dosing and titration
Your prescriber decides every step on the schedule below. The summary here is for orientation while you log treatments - it is not a recommendation.
Wegovy uses a 16-week ramp before the maintenance amount: 0.25 mg for four weeks, then 0.5 mg for four weeks, then 1 mg for four weeks, then 1.7 mg for four weeks, then 2.4 mg as the maintenance amount. Each step is held for at least four weeks before the next increase. 1
The ramp is intended to help the body adjust to the medicine before reaching the maintenance amount. It is not the maintenance amount itself. 1
When you record a treatment in Dosley, you can attach the amount, the day, and any notes about how you tolerated it. The app does not change your schedule - it only records what your prescriber has set.
Injection sites and storage
Wegovy is given by subcutaneous injection in the abdomen, thigh, or upper arm. Rotating sites between treatments is recommended in the prescribing information. 1
Pens should be kept refrigerated between 2°C and 8°C until first use. Wegovy is supplied as single-dose pens; the room-temperature in-use period is set by the prescribing information - follow the limit printed on your packaging or in the patient leaflet. 1
Tracking injection sites and storage windows in Dosley is optional but useful - it gives you a quick view of which sites you have used recently and when a pen needs to be retired or moved.
Wegovy and Ozempic
Wegovy and Ozempic contain the same active ingredient. They are different brand names with different FDA-approved indications.
Semaglutide is sold as Wegovy for chronic weight management and as Ozempic for type 2 diabetes in adults who meet the indication criteria. Each brand has its own FDA-approved labeling, packaging, and patient leaflet, and the maintenance amounts differ. 1 3
Whether you have been prescribed one or the other is a question for your clinician. Dosley supports tracking either brand and treats them as separate treatments.
Missed dose
If a Wegovy injection is missed, the FDA label says it can be taken as soon as possible if more than 2 days remain before the next scheduled day. If 2 days or fewer remain, skip the missed amount and resume on the next regular day. 1
About this medication and Dosley
How often is Wegovy injected?
Wegovy is a once-weekly subcutaneous injection. Your prescriber sets the day of the week and the amount; Dosley records what they have set so you can see your history. 1
What if I forget my Wegovy on the scheduled day?
The FDA-approved label says the missed amount may be taken as soon as possible if more than 2 days remain before the next scheduled day. If 2 days or fewer remain, the missed amount is skipped and you wait until the next regular day. If you are unsure, contact your clinician. 1
What are the most common Wegovy side effects?
In the FDA label's adverse-reaction tables, the most common side effects at the 2.4 mg amount were nausea (about 44%), diarrhea (about 30%), vomiting (about 24%), constipation (about 24%), and abdominal pain (about 20%). Logging side effects in Dosley helps you and your prescriber spot patterns. 1
Is Wegovy the same molecule as Ozempic?
Yes. Both Wegovy and Ozempic contain semaglutide, but each has its own FDA approval, indication, and maintenance amount: Wegovy is approved for chronic weight management and Ozempic is approved for type 2 diabetes. Speak to your clinician about which is appropriate for your situation. 3
Where is Wegovy injected?
The label specifies subcutaneous injection in the abdomen, thigh, or upper arm, with site rotation. Dosley lets you tag the site for each entry so you can see at a glance where you have already injected. 1
How should Wegovy be stored?
The FDA label says Wegovy should be kept refrigerated between 2°C and 8°C until first use. After first use, the pen has a room-temperature in-use window - check the leaflet that came with your pen for the exact number of days. 1
Does Dosley send my Wegovy data to my clinic?
No. Dosley is a personal tracker. Your treatment log lives in your Dosley account, and you choose whether to export it as a PDF to share with your clinician. Talk to your healthcare team before changing anything in your treatment. 1
How Dosley supports a Wegovy routine
Dosley is built for the small rituals of a once-weekly injection routine. The home screen shows your next scheduled day so you never have to count from the calendar, and a quick log entry takes about five seconds - pick the day, the amount you were prescribed, the site, and you are done.
Side-effect notes live next to each entry. Many people find that the early weeks of a new amount bring temporary changes in how they feel; logging those alongside the entry helps you and your prescriber see whether things are settling or whether the schedule needs adjusting.
Weight is tracked in the same place. Manual entry is two taps; a chart shows the trend rather than the daily noise, so a single bad-scale day does not break your week. If you use Apple Health, weight syncs automatically.
Pen tracking helps with the practical side. Each Wegovy pen is used once for one weekly injection, so each entry in Dosley records one pen used; the app reminds you about the storage window in the leaflet you were given.
Everything stays on your device unless you choose otherwise. There is no clinic dashboard, no advertiser, and no requirement to create an account. If your healthcare team asks for a summary, you can export a PDF from the app and share it on your terms.
Track your treatment with Dosley
Log injections, weights, and side effects in a private space designed for GLP-1 routines.
References
- 1. FDA-approved Wegovy (semaglutide) prescribing information (DailyMed)
- 2. Wegovy USPI (Novo Nordisk A/S)
- 3. Drugs@FDA: Wegovy (NDA 215256)
Last reviewed:
Wegovy is a registered trademark of Novo Nordisk A/S. Dosley is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.